Related Experiment Video
Updated: Dec 25, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Effect of Various Invitation Schemes on the Use of Fecal Immunochemical Tests for Colorectal Cancer Screening:
Laura Fiona Gruner1,2, Michael Hoffmeister1, Leopold Ludwig3
1Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Background:
Fecal occult blood testing has been offered for many years in the German health care system, but participation rates have been notoriously low.
Objective:
The aim of this study is to evaluate the effect of various personal invitation schemes on the use of fecal immunochemical tests (FITs) in persons aged 50-54 years.
Methods:
This study consists of a three-armed randomized controlled trial: (1) arm A: an invitation letter from a health insurance plan including a FIT test kit, (2) arm B: an invitation letter from a health insurance plan including an offer to receive a free FIT test kit by mail upon easy-to-handle request (ie, by internet, fax, or reply mail), and (3) arm C: an information letter on an existing colonoscopy offer (ie, control). Within arms A and B, a random selection of 50% of the study population will receive reminder letters, the effects of which are to be evaluated in a substudy.
Results:
A total of 17,532 persons aged 50-54 years in a statutory health insurance plan in the southwest of Germany-AOK Baden-Wuerttemberg-were sent an initial invitation, and 5825 reminder letters were sent out. The primary end point is FIT usage within 1 year from receipt of invitation or information letter. The main secondary end points include gender-specific FIT usage within 1 year, rates of positive test results, rates of colonoscopies following a positive test result, and detection rates of advanced neoplasms. The study was launched in September 2017. Data collection and workup were completed in fall 2019.
Conclusions:
This randomized controlled trial will provide important empirical evidence for enhancing colorectal cancer screening offers in the German health care system.
Trial Registration:
German Clinical Trials Register (DRKS) DRKS00011858; https://bit.ly/2UBTIdt.
International Registered Report Identifier (Irrid):
DERR1-10.2196/16413.

